德國BioNTech(BNTX.US)季度少賺44% 上調復必泰全年銷售下限預測
新冠疫苗復必泰研發商之一德國BioNTech(BNTX.US)公布第三季業績。季度純利17.85億歐元,按年跌44%。每股季度攤薄純利6.98歐元。季度收入34.61億歐元,按年跌43%。
公司預期今年復必泰銷售介乎160億至170億歐元,早前預估為介乎130億至170億歐元。公司9月開始付運針對Omicron變種的更新版新冠疫苗,截至10月中該款疫苗累計預訂量已有約3億劑。
公司亦確認與中國政府商討批准在中國使用復必泰問題,並指討論非常正面。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.